Welcome to our dedicated page for MOTUS GI HOLDINGS news (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on MOTUS GI HOLDINGS stock.
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company headquartered in the United States with subsidiaries in the U.S. and Israel. The company is committed to enhancing endoscopy outcomes, reducing costs, and improving patient experiences. A primary focus of Motus GI is the development and commercialization of the Pure-Vu® System.
The Pure-Vu® System is a medical device designed to improve the colonoscopy experience by aiding in the early detection and prevention of colorectal cancer and other diseases of the colon and rectum. This innovative system, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe, integrates with standard colonoscopes. It facilitates cleaning of a poorly prepared colon during the colonoscopy procedure while maintaining the standard workflow and techniques.
Recent achievements of Motus GI include strengthening their market presence through strategic partnerships and ongoing projects aimed at enhancing the Pure-Vu® System’s functionality and reach. The company continues to focus on securing additional regulatory approvals, expanding its market base, and improving its financial performance.
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced the selection of a poster featuring topline data from the EU study of the Pure-Vu System for presentation at Digestive Disease Week® (DDW) 2022. This premier event for professionals in gastroenterology will be held from May 21-24, 2022. The poster, titled 'An Intracolonoscopy Bowel Cleansing System For Hard-to-Prepare Patients,' will be presented by Milou L.M. van Riswijk, MD, on May 24, 2022, from 12:30 PM to 1:30 PM. DDW highlights significant advancements in GI research, showcasing over 5,000 abstracts and hundreds of lectures.
Motus GI Holdings (NASDAQ: MOTS) will release its first-quarter financial results on May 12, 2022, after market close. A conference call for discussion of results and recent corporate updates will follow at 4:30 p.m. ET. The event will be accessible via a webcast, with a replay available on the company’s website for 90 days. Motus GI specializes in endoscopy solutions aimed at enhancing clinical outcomes and cost-efficiency in gastrointestinal diagnosis and management.
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced the completion of patient enrollment in its EU study evaluating the Pure-Vu System, which aims to improve colonoscopy outcomes for patients with poor bowel preparation. A total of 44 patients enrolled across two sites will use a low volume preparation method. The company plans to present topline study data at a scientific conference in May 2022, focusing on the system's effectiveness in facilitating procedures and potentially reducing costs associated with failed colonoscopies.
Motus GI Holdings, Inc. (NASDAQ: MOTS) reported its financial results for Q4 and the year ended December 31, 2021. The company achieved revenue of $99,000 for Q4 2021, up from $36,000 in Q4 2020, and full-year revenue reached $391,000 compared to $98,000 in 2020. The firm received FDA clearance for its Pure-Vu EVS system, enhancing colonoscopy procedures. However, the company faced a net loss of $4.8 million in Q4 and $19 million for the whole year, affected by the Omicron variant's impact on operations.
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced it will release its fourth quarter and full year financial results on March 29, 2022, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and recent corporate developments. The financial results will provide insights into the company's operational performance, which is critical for investors. The event will be accessible via a webcast, with a replay available on the company's website for 90 days.
Motus GI Holdings, a medical technology company specializing in endoscopy solutions, announced its participation in two key investor conferences in March 2022. The first event is the 32nd Annual Oppenheimer Healthcare Conference from March 15 to 17, where management will engage with investors. The second conference is the LSI Emerging Medtech Summit from March 16 to 18, featuring a presentation on March 16 at 10:40 am PST. Interested investors can contact representatives for meetings.
Motus GI Holdings (NASDAQ: MOTS) announced it received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share, now due by August 22, 2022. The extension follows a previous notification on August 24, 2021, where the company was alerted about its non-compliance status. If the stock reaches the required bid price for 10 consecutive trading days, the issue will be resolved. Otherwise, the company may face delisting, but can appeal if necessary.
Motus GI Holdings has received FDA clearance for its Pure-Vu EVS System, designed to improve colonoscopy procedures. This new system allows for rapid set-up and enhanced navigation, addressing delays caused by insufficient bowel preparation, which affects ~51% of inpatient colonoscopies. With commercialization expected to start immediately, the Pure-Vu EVS aims to facilitate better visualization and overcome challenges in poor colon preparations. The innovative features promise improved usability and efficiency, enhancing the company’s market position and potential profitability.
Motus GI Holdings, scheduled an Innovation Day on January 25, 2022, from 12:30 p.m. to 2:00 p.m. ET. The event will showcase the Pure-Vu EVS System, the third generation of its endoscopy platform, emphasizing commercial expansion and clinical initiatives. The system aims to improve ease of use with features like enhanced navigation and bedside loading, currently under FDA 510(k) review. Keynote speaker Dr. Seth A. Gross will discuss its clinical applicability. The event includes a Q&A session and registration is available online.
Motus GI Holdings, Inc. (NASDAQ: MOTS) has secured U.S. Patent No. 11,185,625 for its innovative colon cleaning system with automatic self-purging features. This advancement in the Pure-Vu® System enhances clinical outcomes during colonoscopies by effectively removing debris and improving visualization. With an estimated 4.8 million inpatient colonoscopy procedures performed in 2021, the patent strengthens Motus GI's position in a market of close to 55 million global procedures annually. The company plans to submit a 510(k) application for the next-generation Pure-Vu EVS by the end of 2021.
FAQ
What is the current stock price of MOTUS GI HOLDINGS (MOTS)?
What is the market cap of MOTUS GI HOLDINGS (MOTS)?
What is Motus GI Holdings, Inc.?
What product is Motus GI known for?
What does the Pure-Vu® System do?
Is the Pure-Vu® System approved for use?
Where is Motus GI Holdings, Inc. located?
What are the recent achievements of Motus GI?
What is the primary focus of Motus GI's current projects?
How does the Pure-Vu® System integrate with colonoscopes?
How does Motus GI contribute to healthcare cost reduction?
Who can I contact for investor information about Motus GI?
